TuHURA Biosciences (NASDAQ:HURA) Trading Down 2.6% – Here’s What Happened

TuHURA Biosciences (NASDAQ:HURAGet Free Report)’s share price dropped 2.6% on Thursday . The company traded as low as $4.66 and last traded at $4.92. Approximately 320,091 shares changed hands during mid-day trading, an increase of 42% from the average daily volume of 224,917 shares. The stock had previously closed at $5.05.

Analyst Ratings Changes

HURA has been the subject of a number of analyst reports. RODMAN&RENSHAW upgraded shares of TuHURA Biosciences to a “strong-buy” rating in a research note on Thursday, December 19th. Maxim Group began coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They issued a “buy” rating and a $15.00 price objective for the company. Finally, Rodman & Renshaw began coverage on shares of TuHURA Biosciences in a research note on Thursday, December 19th. They set a “buy” rating and a $11.00 target price for the company.

Check Out Our Latest Analysis on TuHURA Biosciences

TuHURA Biosciences Trading Down 2.6 %

The stock’s 50 day simple moving average is $4.73.

Hedge Funds Weigh In On TuHURA Biosciences

An institutional investor recently bought a new position in TuHURA Biosciences stock. Apollon Wealth Management LLC bought a new stake in shares of TuHURA Biosciences (NASDAQ:HURAFree Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 61,772 shares of the company’s stock, valued at approximately $253,000. Apollon Wealth Management LLC owned about 0.15% of TuHURA Biosciences at the end of the most recent reporting period. Institutional investors own 0.62% of the company’s stock.

About TuHURA Biosciences

(Get Free Report)

TuHURA Biosciences, Inc (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.

See Also

Receive News & Ratings for TuHURA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TuHURA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.